Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03589339 · ClinicalTrials.gov registry record · Phase 1
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
A Phase 1 study of Metastatic Renal Cell Carcinoma and Squamous Cell Carcinoma of Head and Neck, sponsored by Nanobiotix.
- Active
- Registry status
- Phase 1
- Development phase
- 145
- Enrollment target
- 13
- Study locations
NCT03589339: Active Phase 1 study of Metastatic Renal Cell Carcinoma and Squamous Cell Carcinoma of Head and Neck, sponsored by Nanobiotix.
NCT03589339 is a Phase 1 study of Metastatic Renal Cell Carcinoma and Squamous Cell Carcinoma of Head and Neck that is active but no longer recruiting, run by Nanobiotix. The registered enrollment target is 145 participants, roughly in line with the 139-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target. The trial reports 13 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03589339, a Phase 1 study of Metastatic Renal Cell Carcinoma and Squamous Cell Carcinoma of Head and Neck, is active but no longer recruiting, sponsored by Nanobiotix.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 145 participants
- Enrollment target
- 13
- Study locations
Study Summary
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
Primary Outcome
Determination of DLTs, the MTD (if possible), and RP2Ds for each cohort
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Nivolumab
- RADIATION SABR
- DRUG NBTXR3
Study Locations (13)
Michigan
- Karmanos Cancer Institute - Detroit
- Henry Ford Cancer Institute - Detroit
California
- University of California San Francisco - San Francisco
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Emory University - Atlanta
Illinois
- University of Chicago Medical Center - Chicago
Maryland
- Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center - Baltimore
New Mexico
- Christus St. Vincent Regional Cancer Center - Santa Fe
New York
- Northwell Health - Manhasset
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2019-01-16 |
| Est. Completion | 2027-08-30 |
| Phase | Phase 1 |
What the registry record for NCT03589339 still lists
NCT03589339 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 139-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target.
The record links to 10 conditions, with Metastatic Renal Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03589339 lists 13 locations in 12 states (Michigan, California, Florida).
Frequently Asked Questions
What is clinical trial NCT03589339 about?
NCT03589339 is a clinical study titled "NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy". The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
What is the current status of trial NCT03589339?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2019-01-16. Estimated completion is 2027-08-30.
What conditions does trial NCT03589339 study?
This clinical trial studies the following conditions: Metastatic Renal Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Metastatic Triple-Negative Breast Carcinoma, Immunotherapy, Radiotherapy.
What interventions are being tested in trial NCT03589339?
The interventions under investigation include: Pembrolizumab (DRUG), Nivolumab (DRUG), SABR (RADIATION), NBTXR3 (DRUG).
Who is sponsoring clinical trial NCT03589339?
This trial is sponsored by Nanobiotix, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03589339 being conducted?
This trial has 13 study locations across California, Florida, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03589339's enrollment target sits among peer trials
145 11th of 37 higher than 27 of 37 other Metastatic Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RECRUITING · Phase 1
-
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
RECRUITING · Phase 1
-
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
RECRUITING · Phase 1
-
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
ACTIVE NOT RECRUITING · Phase 1
-
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI